Novartis AG ADR (NVS)vsScienture Holdings, Inc. (SCNX)
NVS
Novartis AG ADR
$148.38
-0.55%
HEALTHCARE · Cap: $273.77B
SCNX
Scienture Holdings, Inc.
$0.36
-5.26%
HEALTHCARE · Cap: $14.33M
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 11844231% more annual revenue ($56.58B vs $477,680). NVS leads profitability with a 23.9% profit margin vs 0.0%. NVS earns a higher WallStSmart Score of 49/100 (D+).
NVS
Hold49
out of 100
Grade: D+
SCNX
Avoid33
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-62.1%
Fair Value
$91.39
Current Price
$148.38
$56.99 premium
Margin of Safety
+21.4%
Fair Value
$0.57
Current Price
$0.36
$0.21 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Reasonable price relative to book value
Revenue surging 449.1% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Revenue declined 0.7%
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
ROE of -0.1% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bull Case : SCNX
The strongest argument for SCNX centers on Price/Book, Revenue Growth, Debt/Equity. Revenue growth of 449.1% demonstrates continued momentum.
Bear Case : NVS
The primary concerns for NVS are Altman Z-Score, Debt/Equity, PEG Ratio.
Bear Case : SCNX
The primary concerns for SCNX are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
NVS profiles as a declining stock while SCNX is a hypergrowth play — different risk/reward profiles.
SCNX is growing revenue faster at 449.1% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
NVS scores higher overall (49/100 vs 33/100), backed by strong 23.9% margins. SCNX offers better value entry with a 21.4% margin of safety. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Scienture Holdings, Inc.
HEALTHCARE · PHARMACEUTICAL RETAILERS · USA
Scienture Holdings, Inc. (SCNX) is a biotechnology firm focused on developing advanced therapeutic solutions for neurological disorders, utilizing an innovative drug development pipeline backed by a skilled research team. With a strong emphasis on addressing unmet medical needs, Scienture is poised to enhance patient outcomes while navigating the complexities of regulatory pathways. The company’s dedication to scientific rigor and its strategic partnerships not only bolster its growth potential but also position SCNX as a significant contributor to advancements in global healthcare. As the demand for effective neurological treatments grows, Scienture aims to leverage emerging opportunities within the expanding healthcare landscape.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?